Download  full announcement Renalytix AI welcomes US Administration’s dedication to advancing American kidney health Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, welcomes the Executive Order signed by the President of the

Download  full announcement Data development plan review continues with FDA under Breakthrough Device Designation Process Performance meets or exceeds targets for identifying Rapid Kidney Function Decline in patients with Type 2 diabetes and existing chronic kidney disease .

Data development plan review continues with FDA under Breakthrough Device designation process; Performance meets or exceeds targets for identifying rapid kidney function decline in patients with Type 2 diabetes and existing chronic kidney disease NEW YORK, July 9, 2019 /PRNewswire/ --  Renalytix AI

Download  full announcement Published data on blood diagnostic for subclinical acute kidney transplant rejection and potential to tailor immunosuppressive therapy Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces positive

Download  full announcement CPT Code a key component for reimbursement from private medical insurance and Medicare Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that the American Medical Association (AMA) has granted

CPT Code a key component for reimbursement from private medical insurance and Medicare   NEW YORK, July 1, 2019 /PRNewswire/ --  Renalytix AI plc  (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the American Medical

Download  full announcement Demonstrates ability to predict early rejection in kidney transplant Supports successful development of a predictive blood test for transplant patients Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease,

Positive study results support successful development of a predictive blood test for transplant patients to meet critical unmet medical need NEW YORK, June 7, 2019 /PRNewswire/ --  Renalytix AI plc  (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease,

Download  full announcement High quality production-scale batches of critical materials successfully produced Key milestone achieved for scaled commercial test production Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces

Download  full announcement Renalytix AI plc(AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that the New York State Department of Health has issued a Clinical Laboratory Improvement Amendment (CLIA)  1  certificate under the Centers for